Purpose: Precise genetic diagnosis of inherited bone marrow failure syndromes (IBMFS), a heterogeneous group of genetic disorders, is challenging but essential for precise clinical decision making.
INTRODUCTION
Inherited bone marrow failure syndromes (IBMFS) are part of a heterogeneous disease category involving a family history in which at least one hematopoietic cell lineage is decreased in the bone marrow. IBMFS consist of more than 25 defined disease entities, including Fanconi anemia (FA), Diamond-Blackfan anemia (DBA), and dyskeratosis congenita (DC). 1 Certain IBMFS have been associated with an increased risk of secondary malignancies. The diagnosis is based on hematological and physical findings with the aid of several disease-specific diagnostic tests such as the chromosomal breakage test for FA and molecular diagnosis with conventional Sanger sequencing for a very limited number of the causative genes. With recent advances in clinical molecular studies that revealed a considerable amount of pathognomonic molecular lesions in IBMFS, [2] [3] [4] the role of genetic tests has become more important in the diagnosis of these diseases. However, because clinical and laboratory findings can overlap among different IBMFS, the selection of targeted genes for genetic diagnosis is difficult. Therefore, a comprehensive genetic diagnostic approach is warranted for patients with a suspicious diagnosis of IBMFS due to the increased number of genes to be analyzed.
Next-generation sequencing (NGS) encompasses a broad range of techniques that enable the simultaneous sequencing of a massive amount of nucleic acid molecules. 5 These complementary approaches include targeted gene sequencing, whole-exome sequencing (WES), and whole-genome sequencing (WGS), each with distinct advantages and disadvantages. Compared with WES/WGS, targeted gene sequencing is a relatively inexpensive approach for the identification of pathogenic mutations in more than 100 genes and has relatively higher sequence coverage. NGS has been used for research studies regarding certain IBMFS, but its clinical utility is limited. Only two studies used targeted gene sequencing with NGS technology to diagnose patients with distinct IBMFS. 6, 7 The majority of these patients had previously undergone extensive genetic testing, all of which yielded negative results. Targeted gene sequencing efficiently identified causative mutations in both studies, which supported the utilization of NGS for genetic screening of patients with IBMFS.
In this study, we developed a targeted gene sequencing platform with 184 genes that were specifically designed for the diagnosis of IBMFS. This platform was used as a first-line diagnostic test for 121 patients clinically diagnosed with IBMFS. In addition, we performed diagnostic WES for 250 patients with IBMFS who could not be genetically diagnosed using conventional genetic tests.
MATERIALS AND METHODS

Patients for targeted sequencing
A total of 121 consecutive patients who were clinically diagnosed with IBMFS at Nagoya University Hospital and other nationwide institutions were included in this study. None of the patients had previously undergone genetic tests. Clinical diagnoses included DBA (n = 26), DC (n = 13), FA (n = 22), Shwachman-Diamond syndrome (SDS, n = 6), severe congenital neutropenia (SCN, n = 7), other anemia (n = 21), other neutropenia (n = 3), other thrombocytopenia (n = 13), and other bone marrow failure (BMF) (cytopenia with ≥2 lineages; n = 10) ( Table 1, Supplementary Table S1 online and Supplementary Figure S1 online).
Whole-exome sequencing of patients
In 2011, we established a government-supported nationwide program, the Research on Measures for Intractable Diseases Project of the Ministry of Health, Labor, and Welfare, for rare inherited blood disorders. As of December 2013, a total of 733 patients were registered with the program (Supplementary Table S1 online) and had clinical diagnoses including FA (n = 117), DBA (n = 110), congenital hemolytic anemia (HA; n = 261), DC (n = 62), congenital dyserythropoietic anemia (CDA; n = 21), congenital sideroblastic anemia (CSA; n = 34), congenital amegakaryocytic thrombocytopenia (CAMT; n = 10), hereditary hemophagocytic lymphohistiocytosis (HLH; n = 65), SCN (n = 47), and unclassified IBMFS (n = 6). Conventional genotyping such as Sanger sequencing had confirmed the clinical diagnoses of 262 patients; however, no causative candidate germline variants were identified (n = 267) or no genotyping was performed (n = 204) for the remaining 471 patients. Of these 471 patients, 250 patients with FA (n = 73), DBA (n = 61), HA (n = 44), DC (n = 29), CDA (n = 12), CSA (n = 9), CAMT (n = 7), HLH (n = 6), SCN (n = 3), and unclassified IBMFS (n = 6) were enrolled in the present study ( 
Sample preparation and next-generation sequencing
Written informed consent was obtained from patients or their legal guardians. This study was approved by the ethics committees of Nagoya University Graduate School of Medicine and Graduate School of Medicine, Kyoto University.
Genomic DNA was extracted from peripheral blood, bone marrow, and Epstein-Barr virus-transformed lymphoblastoid cell lines (EBV-LCL) using a QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany). For targeted sequencing, the target region of the genomic DNA was enriched using SureSelect custom bait (Agilent Technologies, Santa Clara, CA) covering the exons and 10 bases surrounding the exons of 184 genes (Supplementary Table S4 online). For WES, genomic DNA was captured using SureSelect Human All Exon 50M, V4, or V5 Kits (Agilent Technologies). Captured genomic DNA was analyzed by massively parallel sequencing using a HiSeq 2000 or 2500 (Illumina, San Diego, CA) next-generation sequencer with a 100 × 2 paired-end option.
Detection of causative variants
We detected germline variants using our established pipeline (Genomon-exome, http://genomon.hgc.jp/exome/). In brief, sequence reads were aligned to the hg19 reference genome using the Burrows-Wheeler Aligner; variants were detected using our in-house variant caller. Variant allele frequency (VAF) >0.2 (20%) was used as the cut-off value.
Following the guidelines published by the American College of Medical Genetics and Genomics, 8 we removed common single-nucleotide polymorphisms (SNPs) showing minor allele frequency values of more than 1% in (i) the ESP6500 exome variant server (the National Heart, Lung, and Blood Institute Exome Sequencing Project, Seattle, WA; http:// evs.gs.washington.edu/EVS/, as of April 2014); (ii) the 1000 genomes project; 9 or (iii) our in-house SNP database. 10 These variants were considered the causative variants that were previously reported to be pathogenic (category 1) or were otherwise highly expected to cause the associated disorders (e.g., nonsense, frameshift, and splice site variants) (category 2). Other variants of unknown significance such as missense variants without further evidence of pathogenicity were treated as Genetics in meDicine | Volume 19 | Number 7 | July 2017 nondiagnostic in this study. For the specific pathogenicity of each variant, we used the Human Genome Mutation Database (http://www.hgmd.cf.ac.uk/, as of March 2014) and performed an extensive search of the literature in PubMed (http://www. ncbi.nlm.nih.gov/pubmed). The results of the literature search were discussed with physicians who were experts in that particular disease area and genetic diagnoses were made based on the mode of inheritance of each disease. Finally, causative variants were validated by Sanger sequencing.
Using targeted sequencing data, we performed copy-number analysis as described previously. 11 In brief, the coverage of each exon normalized by the mean coverage of the entire sample was compared with that of 12 unrelated reference samples. Exons exhibiting normalized coverage greater than 3 standard deviations from the coverage of reference samples were determined to be candidates for copy-number alterations. All candidate exons were visually inspected using the Integrative Genomics Viewer. 
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RESULTS
Genetic diagnosis by targeted sequencing
Capture-based targeted sequencing covered 99.4% of the target region in 184 genes with more than 20 independent reads. With this coverage, our in-house pipeline detected 227 (201-267) coding variants per patient, of which common SNPs with >1% minor allele frequency accounted for 97% of all detected variants. In total, we identified 69 variants that were considered to be in category 1 (i.e., previously reported alleles) or category 2 (i.e., previously unknown but highly probable variants within known causative genes for each disease subtype). In addition, we were able to identify pathognomonic copynumber aberrations in 11 patients (FANCA (n = 5; UPN-1028, -1082, -1084, -1372, and -1373), RPS17 (n = 3; UPN-1174,
-1186, and -1304), RUNX1 (n = 1, UPN-1222), SBDS (n = 1, UPN-1212), and SPTB (n = 1, UPN-1350) (Figure 1) . We calculated genetic diagnostic rates by our targeted sequencing pipeline based on the estimated mode of inheritance. For instance, we genetically diagnosed patients harboring homozygous or compound heterozygous mutations of known causative genes for autosomal recessive diseases such as FA. Patients with a clinical diagnosis of FA (15/22, 68%) and SDS (4/6, 67%) achieved relatively high genetic diagnostic rates. The genetic diagnosis was achieved in approximately half of the patients with DBA (12/26, 46%) and DC (5/13, 38%). Genetic diagnostic rates of other categories were as follows: SCN (2/7, 29%), other anemia (9/21, 43%), other neutropenia (0/3, 0%), other thrombocytopenia (4/13, 33%), and other BMF (3/10, h UPN-1212 Genetics in meDicine | Volume 19 | Number 7 | July 2017 30%). In total, our targeted sequencing pipeline genetically diagnosed 53 of 121 patients (44%) ( Table 1, Supplementary  Table S1 online). No patient had two or more genetic diagnoses.
Genetic diagnosis by whole-exome sequencing
WES covered more than 80% (56%-91% with SureSelect 50M) to 90% (79-98% with SureSelect V4 or V5) of the coding region with more than 20 independent reads (Supplementary Figure S2 online) . At this coverage level, our in-house pipeline detected 19,574 (13,811-21,945) coding variants per patient. Common SNPs with >1% minor allele frequency accounted for 97% of all detected variants.
We identified 64 category 1 variants (previously reported alleles) and 23 category 2 variants (previously unknown but highly probable variants within known causative genes for each disease subtype) (Supplementary Table S3 online). These 87 variants established genetic diagnoses for 68 (27%) patients ( Table 2) . Diagnostic efficacy was comparable between patients with or without prior genetic testing (26 and 27%, respectively). No patient received more than one genetic diagnosis.
The highest diagnostic efficacy was achieved in patients with FA; in these patients, one or more highly putative causative variants were detected by WES in 35 of 73 patients (48%), followed by DBA (11/61, 18%), HA (7/44, 16%), DC (7/29, 24%), CDA (3/12, 25%), and HLH (3/6, 50%). In contrast, candidate variants were detected or otherwise not identified in only a small fraction of patients with CSA (0/9), CAMT (1/7), and SCN (0/3).
Discordance between clinical diagnosis and genetic variants by targeted sequencing and whole-exome sequencing
In the majority of cases (target sequencing: 45/53, 85%; WES: 63/68, 93%), the detected variants were concordant with, and therefore supported, the clinical diagnoses. However, for the remaining 13 cases (8 patients by target sequencing and 5 patients by WES), the clinical diagnoses were incompatible with the detected variants (Table 3, Supplementary Data online) .
UPN-1350, one of the discordant patients clinically diagnosed with DBA, harbored a known pathognomonic SPTB gene deletion and was genetically diagnosed as hereditary spherocytosis. Two patients with thrombocytopenia (congenital amegakaryocytic thrombocytopenia (UPN-1222) and idiopathic thrombocytopenic purpura (ITP); UPN-1277) were reallocated as familial platelet disorder with propensity to myeloid malignancy (FPD/AML) with RUNX1 gene alterations 12 (microdeletion (UPN-1222, Figure 1 ) and p.P330fs (UPN-1277)). Three patients had IBMFS but not otherwise specified obtained genetic diagnoses as a result of our analysis (UPN-1324, DBA; UPN-1348, SDS; and UPN-1355, FA). Similarly, genetic sequencing analysis corrected the diagnoses of two other patients (UPN-1289 (from DC to SDS) and UPN-1098 (from chronic ITP to von Willebrand disease (VWD) 2B)). In UPN-355, the initial clinical diagnosis was HA, but the detected variants (CDAN1 p.N599S and p.P146fs) supported the diagnosis of CDA. Conversely, in UPN-216 and UPN-485, the suspected clinical diagnosis of CDA was revised to CAMT, congenital amegakaryocytic thrombocytopenia; DBA, Diamond-Blackfan anemia; DC, dyskeratosis congenita; Dx, diagnosis; FA, Fanconi anemia; FPD/AML, familial platelet disorder with propensity to myeloid malignancy; Hetero, heterozygous; ITP, idiopathic thrombocytopenic purpura; IBMFS, inherited bone marrow failure syndrome; NOS, not otherwise specified; SDS, Shwachman-Diamond syndrome; UPN, unique patient number; VWD, von Willebrand disease; WES, whole-exome sequencing.
Volume 19 | Number 7 | July 2017 | Genetics in meDicine HA as a result of identification of mutations (SPTA1 p.R28H in UPN-216 and ANK1 p.R935X in UPN-485) that are typically associated with HA. In these cases, the inconsistency was most likely due to an overlap of clinical phenotypes between HA and CDA; both of which are characterized by hemolysis. In UPN-83, a patient clinically diagnosed with possible CAMT, the genetic diagnosis of DC was reached with causative variants in TINF2 (p.R276X). In UPN-312, the clinical diagnosis of HLH was revised to hyperimmunoglobulin D syndrome, a type of hyperinflammatory syndrome, based on the causative variants in MVK (p.A147T and c.227-1G>A).
DISCUSSION
Recent advances in genetic research identified a large number of causative genes of IBMFS and reinforced the need for a comprehensive genetic diagnostic system in both clinical practice and research. 6 Here, we developed a molecular diagnostic system using WES and a targeted sequencing pipeline covering 184 associated genes for IBMFS. We were successful in providing genetic diagnoses for 53 of 121 patients (44%) by targeted sequencing ( Table 1 ) and for 68 of 250 patients (27%) by WES ( Table 2) . Although the possibility of concomitant diagnoses remains, 13 patients with discordant clinical and genetic diagnoses clearly demonstrated the clinical value of next-generation sequencing ( Table 3) .
The diagnostic rate of our targeted sequencing platform was significantly higher than those demonstrated in a previous study by Zhang et al. 6 (53/121 (44%) vs. 17/85 (20%); P < 0.001), thus reflecting the difference between patient characteristics and genetic regions covered. Although we used a nonbiased approach analyzing 121 consecutive patients who were clinically suspected to have IBMFS without preceding genetic screening, Zhang et al. resequenced patients who remained unclassified after a conventional genetic workup using a sequencing platform with a smaller gene number (85 genes) and a lower coverage rate (>10× coverage in 98.2% of bases). 6 Nine patients in our study had diagnostic variants in four genes that were not included in the gene panel of Zhang et al. (PIEZO1 (n = 2), RPS17 (n = 3), SPTB (n = 3), and VWF (n = 1)). Ghemla et al. reported similar diagnostic rates (59/158, 37%) using a multiplex polymerase chain reaction (PCR) platform covering 72 genes 7 ; however, the detection rate of copy-number variants was significantly lower than that of our study (2/158 (2%) vs. 11/121 (9%); P = 0.003), thus reflecting the superiority of the capture-based platform over multiplex PCR in copy-number analysis. In addition, 10 patients in our study had diagnostic variants in 7 genes that were not included in the gene panel utilized by Ghemla et al. (ALAS2 (n = 1), CDAN1 (n = 1), KLF1 (n = 1), PIEZO1 (n = 2), SLC25A38 (n = 1), SPTB (n = 3), and VWF (n = 1)).
Unsuspected genetic diagnosis has a positive effect on the clinical management of patients, particularly for gene mutations conferring cancer predisposition. Patients with most categories of IBMFS, including DBA, 13 DC, 14 FA, 15 SDS, 16 and SCN, 17 have a significantly higher probability of hematological malignancies than the general population. In addition, we identified three RUNX1 gene alterations (mutation/deletion) among four patients with thrombocytopenia in the targeted sequencing cohort who were diagnosed with FPD/AML. All three patients developed thrombocytopenia during infancy, suggesting that FPD/AML should be included in the differential diagnosis of infantile thrombocytopenia. In total, we genetically diagnosed 43 patients with cancer predisposition in the targeted sequencing cohort (DBA, n = 12; DC, n = 4; FA, n = 16; SDS, n = 6; SCN, n = 2; FPD/AML, n = 3) and 55 patients in the WES cohort (DBA, n = 11; DC, n = 8; FA, n = 35; FPD/AML, n = 1). These patients need to be continually and regularly evaluated by complete blood counts and physical examination to screen for the development of hematological malignancies. In addition, appropriate genetic counseling and familial genetic screening are mandatory. The diagnostic rate of WES was inferior to that of target sequencing (53/121 (44%) vs. 68/250 (27%); P = 0.002), mainly due to the conventional genetic testing conducted before enrollment in the WES cohort. For example, the highest diagnostic rate was demonstrated for FA (15/22, 68%) in the target sequencing cohort, reflecting the ability of the chromosomal breakage test to achieve a precise clinical diagnosis. In contrast, the diagnostic efficacy of WES in patients with FA and prior genetic testing tended to be lower (43%, 25/57), whereas WES in patients with FA without prior genetic testing showed diagnostic rates (62%, 10/16) comparable to that of target sequencing. In addition, our target sequencing platform was able to identify copy-number variants in 11 of 121 patients (9%); however, we could not perform a reliable copy-number analysis in the WES cohort due to relatively low coverage.
Compared to WES, targeted sequencing can achieve similar results at a lower cost for sequencing and computing resources. Although we did not identify any incidental, medically actionable genetic discovery that was not associated with the targeted hematological disease categories in our WES cohort, targeted sequencing could decrease the risk of incidental genetic discovery, which may cause serious ethical problems in a clinical setting. 18 Future accumulation of data regarding genotype-phenotype correlation and functional studies of variants with unknown significance will promote the accuracy of genetic testing for IBMFS. The diagnostic yield of our WES analysis (27%) suggested the insufficiency of current knowledge about missense mutations. A combination of WES and array comparative genomic hybridization, RNA sequencing, and capture sequencing of intron lesions may complement efforts to find small deletion and splicing defects caused by missense, synonymous, and deep-in-intron variants in known causative genes. 19 In addition, WES/WGS applications will certainly identify novel IBMFS causative genes, which should continue to increase the genetic diagnostic rate of next-generation sequencing. 20, 21 In this context, periodic reanalysis of the results is desirable. Furthermore, a meticulous combination of clinical judgment and analysis with genetic information is required.
In summary, we analyzed 371 IBMFS patients with two nextgeneration sequencing platforms and successfully diagnosed 53 of 121 (44%) and 68 of 250 (27%) patients using target sequencing and WES, respectively. Our results demonstrate the efficacy of massive parallel sequencing as a diagnostic tool for IBMFS in clinical practice.
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